Kyntra Bio Q4 And FY25 Revenue Declines; On Track For Phase 2 Trial Analysis Of FG-3246 In H2,2026

(RTTNews) – Kyntra Bio (KYNB) reported financial results for the fourth quarter and full year 2025, reflecting a decline in revenue and provided an update on the pipeline developments ahead.